Compare Stocks: NRIX, KYMR, PRAX, and SYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$107.01 +1.7%	$97.90	$36.65 ▼ $130.05	$8.66B	1.95	584,974 shs	444,447 shs
NRIX Nurix Therapeutics	$23.58 -0.1%	$20.31	$8.19 ▼ $25.08	$2.45B	1.8	1.12 million shs	1.25 million shs
PRAX Praxis Precision Medicines	$307.75 +5.7%	$307.32	$37.19 ▼ $366.52	$8.11B	2.74	326,146 shs	516,296 shs
SYRE Spyre Therapeutics	$101.50 +3.7%	$87.75	$14.51 ▼ $105.09	$8.61B	3.02	1.09 million shs	851,466 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	-0.86%	-4.61%	-3.72%	+29.83%	+140.85%
NRIX Nurix Therapeutics	-2.28%	0.00%	-1.05%	+41.32%	+98.49%
PRAX Praxis Precision Medicines	-1.62%	-6.75%	-16.98%	-8.72%	+420.07%
SYRE Spyre Therapeutics	-2.09%	-1.31%	+8.55%	+31.46%	+483.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$107.01 +1.7%	$97.90	$36.65 ▼ $130.05	$8.66B	1.95	584,974 shs	444,447 shs
NRIX Nurix Therapeutics	$23.58 -0.1%	$20.31	$8.19 ▼ $25.08	$2.45B	1.8	1.12 million shs	1.25 million shs
PRAX Praxis Precision Medicines	$307.75 +5.7%	$307.32	$37.19 ▼ $366.52	$8.11B	2.74	326,146 shs	516,296 shs
SYRE Spyre Therapeutics	$101.50 +3.7%	$87.75	$14.51 ▼ $105.09	$8.61B	3.02	1.09 million shs	851,466 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	-0.86%	-4.61%	-3.72%	+29.83%	+140.85%
NRIX Nurix Therapeutics	-2.28%	0.00%	-1.05%	+41.32%	+98.49%
PRAX Praxis Precision Medicines	-1.62%	-6.75%	-16.98%	-8.72%	+420.07%
SYRE Spyre Therapeutics	-2.09%	-1.31%	+8.55%	+31.46%	+483.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYMR Kymera Therapeutics	2.83	Moderate Buy	$124.48	16.32% Upside
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.00	44.19% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$563.50	83.10% Upside
SYRE Spyre Therapeutics	2.86	Moderate Buy	$101.42	-0.08% Downside

Current Analyst Ratings Breakdown

Latest NRIX, KYMR, PRAX, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	KYMR Kymera Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
7/29/2026	PRAX Praxis Precision Medicines	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$810.00
7/28/2026	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$36.00 ➝ $38.00
7/28/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$125.00 ➝ $135.00
7/28/2026	SYRE Spyre Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
7/22/2026	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $31.00
7/17/2026	KYMR Kymera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NRIX Nurix Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	KYMR Kymera Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$120.00 ➝ $140.00
7/13/2026	PRAX Praxis Precision Medicines	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/13/2026	KYMR Kymera Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$106.00 ➝ $115.00

(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYMR Kymera Therapeutics	$39.21M	224.50	N/A	N/A	$19.42 per share	5.51
NRIX Nurix Therapeutics	$83.98M	29.14	N/A	N/A	$3.88 per share	6.08
PRAX Praxis Precision Medicines	$8.55M	1,003.52	N/A	N/A	$34.85 per share	8.83
SYRE Spyre Therapeutics	$890K	10,029.11	N/A	N/A	$7.21 per share	14.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYMR Kymera Therapeutics	-$311.35M	-$3.57	N/A	N/A	N/A	-611.94%	-24.71%	-22.05%	8/10/2026 (Estimated)
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$13.37	N/A	N/A	N/A	N/A	-43.02%	-40.22%	8/10/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$2.08	N/A	N/A	N/A	N/A	-42.88%	-27.76%	8/4/2026 (Estimated)

Latest NRIX, KYMR, PRAX, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7171	N/A	N/A	N/A	$32.17 million	N/A
8/10/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.6684	N/A	N/A	N/A	$1.25 million	N/A
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.71	N/A	N/A	N/A	N/A	N/A
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million
5/7/2026	Q1 2026	PRAX Praxis Precision Medicines	-$3.58	-$3.20	+$0.38	-$3.20	$0.10 million	N/A
5/5/2026	Q1 2026	SYRE Spyre Therapeutics	-$0.66	-$0.74	-$0.08	-$0.74	$70.87 million	N/A
4/30/2026	Q1 2026	KYMR Kymera Therapeutics	-$0.89	-$0.71	+$0.18	-$0.71	$8.27 million	$34.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYMR Kymera Therapeutics	N/A	10.81	10.81
NRIX Nurix Therapeutics	N/A	6.34	6.34
PRAX Praxis Precision Medicines	N/A	15.88	15.88
SYRE Spyre Therapeutics	N/A	8.97	8.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYMR Kymera Therapeutics	N/A
NRIX Nurix Therapeutics	N/A
PRAX Praxis Precision Medicines	67.84%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
KYMR Kymera Therapeutics	15.98%
NRIX Nurix Therapeutics	6.70%
PRAX Praxis Precision Medicines	3.00%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYMR Kymera Therapeutics	170	82.26 million	69.11 million	Optionable
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable
PRAX Praxis Precision Medicines	110	27.88 million	27.04 million	Optionable
SYRE Spyre Therapeutics	73	87.94 million	74.14 million	Optionable

NRIX, KYMR, PRAX, and SYRE Headlines

Recent News About These Companies

Stempoint Capital LP Buys 135,229 Shares of Spyre Therapeutics, Inc. $SYRE

July 30 at 6:15 AM | marketbeat.com

Wolfe Research Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Peer Perform

July 30 at 2:18 AM | americanbankingnews.com

ADAR1 Capital Management LLC Increases Stock Position in Spyre Therapeutics, Inc. $SYRE

July 29 at 3:03 AM | marketbeat.com

Spyre Therapeutics (SYRE) Expected to Release Quarterly Earnings on Tuesday

July 28 at 9:40 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Cut to "Peer Perform" at Wolfe Research

July 28 at 9:05 AM | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 27 at 4:28 AM | marketbeat.com

Spyre Therapeutics, Inc. $SYRE Stake Decreased by Commodore Capital LP

July 27 at 4:15 AM | marketbeat.com

Spyre Therapeutics, Inc. $SYRE is Affinity Asset Advisors LLC's 6th Largest Position

July 25, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Trading 5.7% Higher - Should You Buy?

July 17, 2026 | marketbeat.com

Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 10.35%

July 14, 2026 | aaii.comA

Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year High After Analyst Upgrade

July 14, 2026 | marketbeat.com

Emerald Advisers LLC Sells 22,744 Shares of Spyre Therapeutics, Inc. $SYRE

July 14, 2026 | marketbeat.com

Spyre Therapeutics Stock Dividends | NASDAQ:SYRE | Benzinga

July 13, 2026 | benzinga.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, Mizuho Analyst Says

July 13, 2026 | marketbeat.com

Candriam S.C.A. Buys 184,748 Shares of Spyre Therapeutics, Inc. $SYRE

July 12, 2026 | marketbeat.com

Jefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)

July 6, 2026 | theglobeandmail.com

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $658,050.00 in Stock

July 3, 2026 | insidertrades.com

Spyre Therapeutics Announces Grants of Inducement Awards

July 2, 2026 | globenewswire.com

Spyre Therapeutics, Inc. $SYRE Stock Holdings Decreased by Pictet Asset Management Holding SA

July 2, 2026 | marketbeat.com

Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data

June 30, 2026 | seekingalpha.com

Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today

June 29, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX, KYMR, PRAX, and SYRE Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

$107.01 +1.76 (+1.67%)

Closing price 04:00 PM Eastern

Extended Trading

$107.05 +0.04 (+0.04%)

As of 07:34 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$23.58 -0.02 (-0.08%)

Closing price 04:00 PM Eastern

Extended Trading

$23.40 -0.18 (-0.76%)

As of 07:48 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Praxis Precision Medicines NASDAQ:PRAX

$307.75 +16.72 (+5.75%)

Closing price 04:00 PM Eastern

Extended Trading

$312.44 +4.69 (+1.53%)

As of 07:34 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Spyre Therapeutics NASDAQ:SYRE

$101.50 +3.63 (+3.71%)

Closing price 04:00 PM Eastern

Extended Trading

$101.56 +0.06 (+0.06%)

As of 07:54 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRIX, KYMR, PRAX, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRIX, KYMR, PRAX, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRIX, KYMR, PRAX, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX, KYMR, PRAX, and SYRE Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

Nurix Therapeutics NASDAQ:NRIX

Praxis Precision Medicines NASDAQ:PRAX

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRIX, KYMR, PRAX, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRIX, KYMR, PRAX, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRIX, KYMR, PRAX, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX, KYMR, PRAX, and SYRE Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

Nurix Therapeutics NASDAQ:NRIX

Praxis Precision Medicines NASDAQ:PRAX

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools